Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;4(3):89-98.
doi: 10.1007/s44228-022-00012-8. Epub 2022 Jul 11.

Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation

Sayako Yuda  1 , Shigeo Fuji  2 , Bipin Savani  3 , Katie S Gatwood  3
Affiliations
Review

Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation

Sayako Yuda et al. Clin Hematol Int. 2022 Sep.

Abstract

Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT. While several guidelines for the antiemetic therapy against CINV have been published, there is no detailed information about appropriate antiemetic drugs for each conditioning regimen in HSCT. Various studies reported that the triplet of 5-HT3RA, NK1RA, and dexamethasone appears useful in HSCT. However, each antiemetic has unique adverse effects or interactions with specific drugs. Here, we review the literature relating to clinical trials on the prevention of CINV, and summarize the information to clarify the benefit of antiemetic regimens.

Keywords: Antiemetics; Hematopoietic cell transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors had no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Impact of antiemetics on the clinical outcome after HSCT a without appropriate antiemetic regimen, b under appropriate antiemetic regimen. EN enteral nutrition, PN parenteral nutrition, GVHD graft-versus-host disease, QoL quality of life, TRM transplant-related mortality
See this image and copyright information in PMC

References

    1. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–2797. doi: 10.1200/JCO.20.01296. - DOI - PubMed
    1. Smith P, Lavery A, Turkington RC. An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management. Best Pract Res Clin Gastroenterol. 2020;48–49:101691. doi: 10.1016/j.bpg.2020.101691. - DOI - PubMed
    1. Trigg ME, Inverso DM. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transplant. 2008;42(8):501–506. doi: 10.1038/bmt.2008.257. - DOI - PubMed
    1. Tendas A, Niscola P, Perrotti A, Dentamaro T, de Fabritiis P, Arcese W. Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need. Support Care Cancer. 2015;23(8):2211. doi: 10.1007/s00520-015-2711-z. - DOI - PubMed
    1. Tendas A, Sollazzo F, Bruno A, Cupelli L, Niscola P, Pignatelli AC, et al. Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant. Support Care Cancer. 2012;20(5):891–892. doi: 10.1007/s00520-012-1411-1. - DOI - PubMed

LinkOut - more resources